MedTrace Logo

A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma

NCT04886765 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 238

Last updated 2021-05-14

No results posted yet for this study

Summary

This is a phase I / II, multi-center, single-arm, open-label study to evaluate the safety and efficacy of ALMB-0168 in patients with osteosarcoma whose prior standard treatment have failed.

Conditions

Interventions

DRUG

ALMB-0168

ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.

Sponsors & Collaborators

  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

    collaborator INDUSTRY

  • AlaMab Therapeutics (Shanghai) Inc.

    lead INDUSTRY

Principal Investigators

  • Jingnan Shen, Doctor · the first affiliated Hospital, Sun Yat-sen Unibersity

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-31
Primary Completion
2023-11-30
Completion
2024-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04886765 on ClinicalTrials.gov